Psoriatic arthritis data for Tremfya and Otezla presented at EULAR

15 June 2018

Small molecule and biologic go head to head at the Annual European Congress of Rheumatology (EULAR) in Amsterdam on Friday morning, with oral presentations from Celgene (Nasdaq: CELG) and Janssen in psoriatic arthritis.

Celgene hopes that its real-world data-driven results, which show new benefits of Otezla (apremilast) against key domains of the disease, will help prop up the oral medicine’s blockbuster status.

Otezla, an inhibitor of phosphodiesterase 4 (PDE4), has a unique mechanism of action for this indication, and brought in $371 million for the company in the final quarter of last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK